Dr Reddy’s secures thrombosis drug rights in $17.5m deal
Indian pharmaceutical company Dr Reddy’s has agreed a deal to buy global intellectual property rights to a generic version of GSK’s deep vein thrombosis (DVT) treatment Arixtra (fondaparinux sodium) as part of a $17.5 million deal with a partner company.
A generic version of the drug is produced by Alchemia, an Australian partner of Dr Reddy’s, but the pair has agreed to assign all rights to Dr Reddy’s.
The deal, announced on November 18, was approved at Alchemia’s annual general meeting on November 10.
A spokesman for Dr Reddy’s told LSIPR: “Many aspects of drug products, including generic products, can be the subject of patent protection.
“The patent portfolio purchased by Dr Reddy’s covers methods of making the product and prevents others from using its particularly robust processes until at least 2022.”
Arixtra is approved in the US and Europe for the treatment of DVT and pulmonary embolism and is also used to prevent DVT after major surgery.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk